首页> 美国卫生研究院文献>Leukemia Supplements >Antibiotic therapy in hematological neutropenic patients: what is the news?
【2h】

Antibiotic therapy in hematological neutropenic patients: what is the news?

机译:血液中性白细胞减少症患者的抗生素治疗:这是什么消息?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bacterial infection is a very common complication in hematological neutropenic patients whose treatment is extremely challenging for several reasons. First, they are frequently caused by resistant pathogens (multidrug resistant (MDR)), and this may limit the availability of effective therapeutic weapons. Second, these patients often present peculiar pathophysiological conditions that may alter the pharmacokinetic behavior of antimicrobials, and this may explain the need for a new administration schedule and new dosing regimens of antibiotics in this setting. In an era in which there are only few new therapeutic weapons for the treatment of MDR bacterial infections, while advocating for new drugs, what could be effectively done nowadays is to increase the knowledge on appropriateness of the use of currently available drugs to improve clinical outcome and to preserve their activity.
机译:细菌感染是血液中性白细胞减少症患者的非常常见的并发症,由于多种原因,其治疗极具挑战性。首先,它们经常是由耐药菌引起的(多药耐药性(MDR)),这可能会限制有效治疗武器的可用性。其次,这些患者经常表现出特殊的病理生理状况,可能会改变抗微生物药的药代动力学行为,这可能解释了在这种情况下需要新的给药方案和新的抗生素给药方案。在一个只有很少的新药可以治疗MDR细菌感染的时代,同时提倡使用新药,如今可以有效地做的事情是增加对使用现有药物的适宜性的认识,以改善临床结果并保留其活动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号